Sign in

Private company

Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. is a pharmaceutical preparations company in the Cayman Islands.1 It is headquartered in Shanghai, China.1

Last updated Oct 21, 2026.

Overview

-$88.1MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersShanghai, China1
  • Incorporated inCayman Islands3
  • Business addressBuilding 3, 418 Guilin Road, Xuhui District, Shanghai, F4 2000303
  • Filer categoryAccelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-44.2%Return on equity2
0.03×Debt to equity2
-$77.0MFree cash flow2

Financial statements

Operating income452-$90.6M in 2022+176% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$32.9M-$32.9M20202021: -$72.7M-$72.7M2021+121%2022: -$90.6M-$90.6M2022+24%
Net income452-$88.1M in 2022+171% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$32.5M-$32.5M20202021: -$70.9M-$70.9M2021+118%2022: -$88.1M-$88.1M2022+24%
Fiscal year2019202020212022
Research and development$25.9M4$51.3M5$70.4M2
Operating income-$32.9M4-$72.7M5-$90.6M2
Interest$330.0K4$794.0K5$977.0K2
Income before tax-$70.9M5-$88.1M2
Income tax$04$3.0K2
Net income-$32.5M4-$70.9M5-$88.1M2
Earnings per share-$0.424-$0.225-$0.262
Earnings per share (diluted)-$0.424-$0.225-$0.262
Shares (weighted, basic)328.9M shares2338.3M shares2
Shares (weighted, diluted)328.9M shares2338.3M shares2

Compare Gracell Biotechnologies Inc. with another company

Corporate structure

Gracell Biotechnologies Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Gracell Biotechnologies Inc.

  • Gracell Biotechnologies Inc. Shanghai, China

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Gracell Biotechnologies Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$37.2M2 Dec 31, 2022$31.2M5 Dec 31, 2021+19.4%
Accumulated depreciation$19.4M2 Dec 31, 2022$11.7M5 Dec 31, 2021+65.0%
Property and equipment, net$17.9M2 Dec 31, 2022$19.4M5 Dec 31, 2021−8.1%
Operating-lease assets (leased space)$3.1M2 Dec 31, 2022$4.7M5 Dec 31, 2021−32.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$210.9M2 Dec 31, 2022$287.0M5 Dec 31, 2021−26.5%
Marketable securities, current$516.0K2 Dec 31, 2022$567.0K5 Dec 31, 2021−9.0%

Inventory

ItemLatestA year beforeChange
Raw materials$210.0K2 Dec 31, 2022

Filings

102 filings to the SEC since October 2021: 2 annual reports, 23 large holders, 77 other. The latest 20:

  1. Mar 4, 202415-12G EDGAR
  2. Feb 27, 2024EFFECT EDGAR
  3. Feb 27, 2024EFFECT EDGAR
  4. Feb 26, 2024S-8 POS EDGAR
  5. Feb 26, 2024POS AM EDGAR
  6. Feb 26, 2024POS AM EDGAR
  7. Feb 26, 2024S-8 POS EDGAR
  8. Feb 22, 20246-K EDGAR
  9. Feb 20, 20246-K EDGAR
  10. Feb 14, 2024SC 13G EDGAR
  11. Feb 14, 2024SC 13G/A EDGAR
  12. Feb 14, 2024SC 13G/A EDGAR
  13. Feb 13, 2024SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G EDGAR
  14. Feb 13, 2024SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G EDGAR
  15. Jan 30, 20246-K EDGAR
  16. Jan 17, 20246-K EDGAR
  17. Jan 8, 20246-K EDGAR
  18. Jan 2, 20246-K EDGAR
  19. Dec 26, 20236-K EDGAR
  20. Dec 22, 20236-K EDGAR

The 102 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Gracell Biotechnologies Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGracell Biotechnologies Inc.1
  • CIK0001826492
  • Filer statusAccelerated filer<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressBuilding 3, 418 Guilin Road, Xuhui District, Shanghai, F4 2000301
  • Phone008621640315221
  • Shares outstanding338,498,819 as of Dec 31, 20222
  • On EDGAR sinceOct 19, 20201
  • Filings148 in all: 6-K (52), CORRESP (13), SC 13G (11), SC 13G/A (11), UPLOAD (11), 144 (9), EFFECT (6), 20-F (3)1
    All 29 form types

    F-1/A (3), F-3/A (3), DRSLTR (2), F-3 (2), POS AM (2), S-8 (2), S-8 POS (2), SC 13D (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), F-1 (1), F-6 (1), F-6/A (1), FWP (1), SC 13D/A (1)

  • Latest filingsAnnual report (20-F) Apr 25, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16